RÉSUMÉ
Challenges for glioma treatment with nanomedicines include physio-anatomical barriers (the blood-brain barrier and blood-brain tumor barrier), low drug loading capacity, and limited circulation time. Here, a red blood cell membrane-coated docetaxel drug nanocrystal (pV-RBCm-NC(DTX)), modified with pHA-VAP (pV) for all-stage targeting of glioma, was designed. The NC(DTX) core exhibited a high drug loading capacity but low in vivo stability, and the RBCm coating significantly enhanced the stability and prolonged in vivo circulation. Moreover, the Y-shaped targeting ligand pV was modified by a mild avidin-biotin interaction, which endowed RBCm-NC(DTX) with superior barrier-crossing ability and therapeutic efficacy. The integration of nanocrystal technology, cell membrane coating, and the avidin-biotin insertion method into this active targeting biomimetic formulation represents a promising drug delivery strategy for glioma.
Sujet(s)
Antinéoplasiques , Tumeurs du cerveau , Docetaxel , Membrane érythrocytaire , Gliome , Nanoparticules , Docetaxel/administration et posologie , Docetaxel/pharmacocinétique , Docetaxel/composition chimique , Gliome/traitement médicamenteux , Animaux , Nanoparticules/composition chimique , Antinéoplasiques/administration et posologie , Antinéoplasiques/pharmacocinétique , Antinéoplasiques/composition chimique , Antinéoplasiques/usage thérapeutique , Membrane érythrocytaire/effets des médicaments et des substances chimiques , Membrane érythrocytaire/composition chimique , Lignée cellulaire tumorale , Tumeurs du cerveau/traitement médicamenteux , Mâle , Systèmes de délivrance de médicaments , Avidine/administration et posologie , Avidine/composition chimique , Humains , Biotine/composition chimique , Biotine/administration et posologie , Rat Sprague-Dawley , Barrière hémato-encéphalique/métabolisme , Souris de lignée BALB C , Souris nudeRÉSUMÉ
The existence of the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) greatly limits the application of chemotherapy in glioma. To address this challenge, an optimal drug delivery system must efficiently cross the BBB/BBTB and specifically deliver therapeutic drugs into glioma cells while minimizing systemic toxicity. Here we demonstrated that glucose-regulated protein 78 (GRP78) and dopamine receptor D2 were highly expressed in patient-derived glioma tissues, and dopamine receptors were highly expressed on the BBB. Subsequently, we synthesized a novel "Y"-shaped peptide and compared the effects of different linkers on the receptor affinity and targeting ability of the peptide. A peptide-drug conjugate (pHA-AOHX-VAP-doxorubicin conjugate, pHA-AOHX-VAP-DOX) with a better affinity for glioma cells and higher solubility was derived for glioma treatment. pHA-AOHX-VAP-DOX could cross both BBB and BBTB via dopamine receptor and GRP78 receptor, and finally target glioma cells, significantly prolonging the survival time of nude mice bearing intracranial glioma. Furthermore, pHA-AOHX-VAP-DOX significantly reduced the toxicity of DOX and increased the maximum tolerated dose (MTD). Collectively, this work paves a new avenue for overcoming multiple barriers and effectively delivering chemotherapeutic agents to glioma cells while providing key evidence to identify potential receptors for glioma-targeted drug delivery.